Overexpression of p53 protein and its significance for recurrent progressive bladder tumours

British Journal of Urology

Volumn 77, Issue 5, 1996, Pages 659-666

  Underwood, M A ^a,b,c,d   Reeves Smith, J ^a   Gardiner, D S ^a   Scott, R ^a   Bartlett, J ^a   Cooke, T G ^a  

^a University Department of Surgery   (United Kingdom)

^b Department of Pathology ^*  (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bladder cancer; p53 Immunohistochemistry; p53 Overexpression; Prognosis

Indexed keywords

POLYCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT CANCER; TRANSITIONAL CELL CARCINOMA;

EID: 0030420270     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1996.09386.x     Document Type: Article

References (25)

1. McBride OW, Merry D. Givol D. The gene for human p53 cellular tumour antigen is located on chromosome 17 short arm (1 7p 13). I'roc Nail Acad Sei USA 1986: 83: 130-4
2. Miller C, Simon K, Aslo A et al. p53 mutations in human lung tumours. Cancer Res 1992: 52: 1695-8
3. Soussi T. Caron de Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncoaene 1990; 5: 945-52
4. Diller L. Kassel J. Nelson CE et al. P53 function as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990; 10: 5772-81
5. Livingstone LR, White A. Sprouse J, Livanos E. Jacks T. Tisty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. Cell 1992; 70: 923-35
6. Yin Y, Tainsky MA, Bischoff FZ. Strong LC. Wahl GM. Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 957-48
7. Yonish-Rouach E. Resnitzky D. Lotem J, Sachs L. Kimchi A. Oren M. Wild type p53 restores induces apoptosis of myeloid leukeamic cells that is inhibited by interleukin 6. Mature 1991: 352: 345-7
8. Katson MB. Xahn QM, Eldeiry WS et al. A mammalian cell cycle checkpoint pathway utilising p53 and CADD45 is defective in Ataxia-Telangiectasia. Cell 1992; 71: 587-97
9. Lane DP. p53. guardian of the genome. Nature 1992: 356: 15-6
10. Levine AJ. Momand J. Finlav CA. The p5 5 tumour suppressor gene, Nature 1991: 551: 453-6
11. Kirk D. Improving the management of superficial bladder cancer. Br Mat J 1993: 306: 1014-5
12. Midgely CA. Fisher CJ. Bartek J, Vojtesek B. Lane D. Barnes DM. Analysis of p53 expression in human tumours: an antibody raised against human p 5 3 expressed in Escherichia coli. J Cell Science 1992: 101: 183-9
13. 3 Hsu SM. Raine L. Fanger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cijtochem 1981: 29: 577-82
14. Cox DR. Regression models and life tables. J Roy Statist Soc B 1972: 34: 187-220
15. Peto R, Pyke MC. Armatage NE. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II Analysis and examples. Br J Cancer 1977: 35: 53-8
16. Bland JM. Altmann DC. Statistical methods for assessing agreement between two methods of clinical measure. Lancet 1986: 1. 8476: 307-10
17. Fujimoto K, Yamada Y, Okajima F, et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992: 52: 1393-8
18. Sidransky D. Eschenbach AV. Tsai YC et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252: 706-9
19. Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Jnt J Cancer 1993: 53: 365-70
20. Sarkis AS. Dalbagni C. Cordon-Cardo C et ni. Nuclear overexpression ol' p5 5 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl CHMCT lust 1993: 85: 53.
21. Gardiner RA. Walsh MD. Alien V ct til. Immunohistological expression of p53 in primary pTl transitional cell bladder cancer in relation to tumour progression, ttr J lirol 1944: 73: 526-32
22. Tliomas DJ, Robinson MC, Charlton R. Wilkinson S. Shenton BK. Neal OF. p53 expression, ploidy and progression in pTl transitional cell carcinoma of the bladder. 994: 73: S 3 3-7
23. Sarkis AS. Dalbagni G, Cordon-Cardo C et til. Association of p53 nuclear overexpression and tumour progression in carcinoma in situ of the bladder. J Urol 1994: 152: 388-92
24. Vet JAM, Bringuier PP. Poddighe P|. Karthaus HFM. Debruyne FMJ, Schalken JA. p53 mutations have no additional prognostic value over stage in bladder cancer. Rr I Cancer 1994: 70: 496-500
25. Fearon FR. Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67